Evidence map›Paper›PMID 40850370›Full record

ArticleContemporary clinical trials2025

Multi-hospital electronic decision support for drug-associated acute kidney injury (MEnD-AKI): Study protocol for a randomized clinical trial.

Britney A Stottlemyer, John A Kellum, Azra Bihorac, Tezcan Ozrazgat-Baslanti, Raghavan Murugan, Chung-Chou Ho Chang, Nabihah Amatullah, Tiffany L Tran, Caiden J Lukan, Michele M Elder and 6 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Britney A StottlemyerUniversity of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
John A KellumCenter for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Azra BihoracIntelligent Clinical Care Center, University of Florida, Gainesville, FL, USA; Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, FL, USA.
Tezcan Ozrazgat-BaslantiIntelligent Clinical Care Center, University of Florida, Gainesville, FL, USA; Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, FL, USA.
Raghavan MuruganCenter for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Chung-Chou Ho ChangDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Nabihah AmatullahUniversity of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Tiffany L TranUniversity of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Caiden J LukanUniversity of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Michele M ElderCenter for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Esra AdiyekeIntelligent Clinical Care Center, University of Florida, Gainesville, FL, USA; Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, FL, USA.
Yuanfang RenIntelligent Clinical Care Center, University of Florida, Gainesville, FL, USA; Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, FL, USA.
Dan RickettsHealth Sciences Information Technology, University of Pittsburgh, Pittsburgh, PA, USA.
Beth EmanueleHealth Sciences Information Technology, University of Pittsburgh, Pittsburgh, PA, USA.
Parisa RashidiIntelligent Clinical Care Center, University of Florida, Gainesville, FL, USA; Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.
Sandra L Kane-GillUniversity of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC, Department of Pharmacy and Therapeutics, Pittsburgh, PA, USA. Electronic address: SLK54@pitt.edu.

Funding

(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKIR01DK121730 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BIHORAC, AZRA, KANE-GILL, SANDRA L · 2021 to 2025
$3.2M
NIDDK NIH HHS R01 DK121730
6 · The paper itself

Abstract

BACKGROUND AND

objectivesTools to assist with drug management for both nephrotoxic medications and renally eliminated drugs are urgently needed. "Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury" (MEnD-AKI) aims to examine the effect of a pharmacist-led intervention augmented with predictive analytics in the form of electronic alerts delivered to pharmacists followed by drug management recommendations provided to physicians via telemedicine for the early management of patients at risk of developing AKI or progressing to higher AKI stages.

designProspective, multi-site, cluster-randomized clinical trial.

settingEight hospitals within the UPMC health system. PATIENTS: Attending physicians belonging to primary services other than intensive care or organ transplant will be eligible for participation in the study. The unit of randomization is physician hospital services (clusters), and outcomes will be assessed for patients cared for by these physicians.

interventionsResearchers will randomize 38 hospital service clusters to receive: 1) electronic medical record (EMR)-based AKI passive alert, which is standard of care at UPMC; this alert provides the diagnosis and staging of AKI but without recommendations for management; or 2) protocolized, tiered pharmacist-led intervention augmented with near-realtime predictive analytics in the form of automated alerts incorporated into a web application delivered to pharmacists followed by drug management recommendations provided to physicians via telemedicine for consideration and approval. OUTCOMES: The primary outcome is major adverse kidney events (MAKE) measured within 30 days of admission. Secondary outcomes include progression of AKI, AKI duration, and nephrotoxic burden. CLINICAL TRIALS REGISTRATION: ClinicalTrials.govNCT06264752 (v2).

Indexed as

Acute Kidney InjuryDecision Support Systems, ClinicalElectronic Health RecordsPharmacistsHumansMulticenter Studies as TopicPharmacy Service, HospitalProspective StudiesRandomized Controlled Trials as TopicTelemedicineAcute kidney injuryAdverse drug reactionsArtificial intelligenceDecision support systemDrug managementDrug safetyTelemedicine

Identifiers

PMID40850370
PMCPMC12967209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.